BRIEF—Nippon Shinyaku and J&J to co-promote Erleada in Japan

Nippon Shinyaku has inked a co-promotion agreement with Johnson & Johnson’s pharmaceuticals arm, Janssen, related to Erleada (apalutamide), a novel oral androgen receptor inhibitor.

Pending approval for people with castration-resistant prostate cancer, Nippon will help Janssen promote the drug in Japan, while Janssen will retain the marketing authorization.

Nippon Shinyaku president Shigenobu Maekawa said: “Urology is one of the most important disease areas for us, we look forward to ensuring broad and rapid access to apalutamide with this strategic agreement.”